JPRN-UMIN000005250已完成未知
Efficacy of ezetimibe for the treatment of non-alcoholic fatty liver disease: A randomized, controlled trial - Efficacy of ezetimibe for the treatment of non-alcoholic fatty liver disease: A randomized, controlled trial
Eishiro Mizukoshi0 个研究点目标入组 80 人开始时间: 2011年3月14日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients will be excluded from the study if they meet any of the following criteria: 1)hepatic virus infections (hepatitis B and C) 2)the current or past consumption of more than 20 g of alcohol daily 3)concurrent hepatocellular carcinoma, as determined by diagnostic imaging results 4) hepatic encephalopathy 5) active infections 6) severe complication 7) Woman who has possibility of pregnancy or pregnancy or while suckling. 8)Case to whom medicine in which it is using together taboo of ezetimibe and describes attention of using together is administered 9) those who are inadequate for this study as assessed by the investigators
研究者
相似试验
已完成
不适用
Efficacy of Ezetimibe for the patients with Non-alcoholic fatty liver disease (NAFLD)JPRN-UMIN000001071Osaka City University Graduate School of Medicine60
已完成
2 期
Ezetimibe Versus Placebo in the Treatment of Non-alcoholic SteatohepatitisNon Alcoholic SteatohepatitisNCT01766713University of California, San Diego50
已完成
3 期
Therapeutic fficacy of ezetimibe in patients with nonalcoholic steatohepatitis (NASH): a pilot study.onalcoholic steatohepatitis (NASH)JPRN-UMIN000001258Division of Gastroenterology, Yokohama City University Hospital10
已完成
不适用
A study on efficacy of Ezetimibe in patients with Dyslipidemia associated with Digestive disease-Its effect on biliary bigly metabolismhypercholesterolemiaJPRN-UMIN000004183Hiroshima University hospital Department of General Medicine60
招募中
不适用
Effects of ezetimibe combination therapy for patients with atherosclerotic cardiovascular disease; randomized comparison of LDL-cholesterol targeting <70 versus <55mg/dL; Ez-PAVE trialDiseases of the circulatory systemKCT0005547Yonsei University Health System, Severance Hospital3,048